Literature DB >> 22510913

[Molecular test Genotype® MTBDRplus, an alternative to rapid detection of multidrug resistance tuberculosis].

Luis Asencios1, Marco Galarza, Neyda Quispe, Lucy Vásquez, Elena Leo, Eddy Valencia, Juan Ramírez, Margoth Acurio, Rosario Salazar, Alberto Mendoza-Ticona, Omar Cáceres.   

Abstract

The Genotype®MTBDRplus molecular test is a method that allows identification of the most frequent mutations associated with resistance to major first-line antituberculosis drugs, Isoniazid (INH) and Rifampicin (RFP). The aim of this study was to evaluate the performance of the molecular test with culture and smear- positive sputum samples. We evaluated 95 cultures and 100 sputum samples with resistance profiles previously determined by the reference method "Agar Plate Proportions" (APP). The molecular test from cultures showed a sensitivity of 100 %, 97,5 % and 96,97 % for RIF, INH and MDR respectively while from sputums the sensitivity was 95,65 %, 96,77 % and 95,24 % for RIF, INH and MDR respectively. We conclude that the molecular test Genotype®MTBDRplus is a very useful tool to detect resistance to isoniazid and rifampicin simultaneously (MDR-TB) in up to 72 hours from sputum samples or cultures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22510913     DOI: 10.1590/s1726-46342012000100014

Source DB:  PubMed          Journal:  Rev Peru Med Exp Salud Publica        ISSN: 1726-4634


  5 in total

1.  Predictive value of molecular drug resistance testing of Mycobacterium tuberculosis isolates in Valle del Cauca, Colombia.

Authors:  Beatriz E Ferro; Pamela K García; Luisa Maria Nieto; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

2.  Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis.

Authors:  Jimena Collantes; Francesca Barletta Solari; Leen Rigouts
Journal:  Am J Trop Med Hyg       Date:  2016-10-24       Impact factor: 2.345

3.  The fourth national anti-tuberculosis drug resistance survey in Peru.

Authors:  N Quispe; L Asencios; C Obregon; G E Velásquez; C D Mitnick; M Lindeborg; H Jave; L Solari
Journal:  Int J Tuberc Lung Dis       Date:  2020-02-01       Impact factor: 2.373

Review 4.  Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  Ruvandhi R Nathavitharana; Patrick G T Cudahy; Samuel G Schumacher; Karen R Steingart; Madhukar Pai; Claudia M Denkinger
Journal:  Eur Respir J       Date:  2017-01-18       Impact factor: 16.671

5.  Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.

Authors:  Jose Gabriel Cornejo Garcia; Valentina Antonieta Alarcón Guizado; Alberto Mendoza Ticona; Edith Alarcon; Einar Heldal; David A J Moore
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.